Fasenra: Clinical Trials

4 trials of Fasenra, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 unknown. 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Unknown 2
Phase 31Completed 1

Follow Fasenra: new trials by email Literature Review of Fasenra trials Research Report on Fasenra

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Benralizumab Initiated During Severe Asthma Attack
Benralizumab 30 MG/ML [Fasenra], Placebos - Asthma Attack, Asthma
Phase 2UnknownSingapore General Hospital1282021-06-022021-07-23
Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)
Benralizumab, Prednisolone - Asthma, COPD
Phase 2UnknownUniversity of Oxford1582021-03-292024-01-23
Benralizumab for Eosinophilic Gastritis (BEGS)
Benralizumab, Placebo - Eosinophilic Gastritis or Gastroenteritis
Phase 2 / Phase 3CompletedChildren's Hospital Medical Center, Cincinnati262018-04-232022-02-03
Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
Benralizumab, Placebo - Chronic Rhinosinusitis (Diagnosis), Nasal Polyps
Phase 2CompletedJohns Hopkins University332017-07-012021-02-11

Conditions studied

Asthma (2)  ·  Disease (1)  ·  Eosinophilia (1)  ·  Eosinophilic enteropathy (1)  ·  Gastroenteritis (1)  ·  Nasal Polyps (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Sponsors

Children's Hospital Medical Center, Cincinnati (1)  ·  Johns Hopkins University (1)  ·  Singapore General Hospital (1)  ·  University of Oxford (1)

Countries

United States (2)  ·  Singapore (1)  ·  United Kingdom (1)

Top investigators

Jody Tversky, MD (1)  ·  Marc E Rothenberg, MD, PhD (1)  ·  Mariko Koh (1)  ·  Mona Bafadhel, PhD, MBChB (1)

Results publications

PMID 25445859, PMID 27609406, PMID 27609408, PMID 31310686, PMID 33595845, PMID 34110505, PMID 37336228, PMID 39615502

NIH funding

2018 (1)